-
公开(公告)号：US20220106402A1
公开(公告)日：2022-04-07
申请号：US17423602
申请日：2020-01-17
发明人： Heather J. BAX , James F. SPICER , Debra H. JOSEPHS , Giulia PELLIZZARI , Sophia N. KARAGIANNIS
摘要： In one aspect, the present invention relates to an immunoglobulin E (IgE) for use in repolarizing macrophages from a first phenotype to an anti-tumor phenotype in the treatment of cancer in a subject; wherein the first phenotype comprises a quiescent (M0) macrophage phenotype or an anti-inflammatory (M2a) macrophage phenotype; and the anti-tumor phenotype comprises a newly polarized macrophage phenotype characterized by expression of the following cytokines and chemokines: tumor necrosis factor alpha (TNFα); interferon-gamma (IFNγ); interleukin-1beta (IL-1β); interleukin-6 (IL-6); Regulated on Activation, Normal T cell Expressed and Secreted (RANTES or CCL5); and/or interleukin-10 (IL-10).
-
公开(公告)号：US20220088131A1
公开(公告)日：2022-03-24
申请号：US17355029
申请日：2021-06-22
IPC分类号： A61K38/17 , A61K45/00 , C07K14/47 , G01N33/50 , G01N33/564 , G01N33/68 , C07K14/54 , C07K14/57 , A61K47/64 , A61K38/48 , A61K45/06 , C12N5/0783 , C12N15/113 , C12N15/115
摘要： In some aspects, provided herein is a method of enhancing production of interleukin-17 (IL-17), interferon gamma (IFN-γ), or both by a mammalian T cell, the method comprising contacting the cell with a C5L2 inhibitor. In some aspects, provided herein is a method of enhancing Th1 and/or Th17 responses by a mammalian T cell, the method comprising contacting the cell with a C5L2 inhibitor. In some aspects, provided herein is a method of enhancing production of interleukin-6 (IL-6), interleukin 1 beta (IL-1β), or both by a mammalian T cell or monocyte, the method comprising contacting the cell with a C5L2 inhibitor. In some aspects, provided herein is a method of decreasing suppressive activity of a T regulatory cell, e.g., a natural regulatory T (nTreg) cell, the method comprising contacting a Treg cell, e.g., an nTreg cell, with an inhibitor of C5L2.
-
公开(公告)号：US20220054548A1
公开(公告)日：2022-02-24
申请号：US17415262
申请日：2019-12-20
发明人： Graham Michael Lord
IPC分类号： A61K35/17 , C12N5/0783 , C12N15/113 , A61P37/06
摘要： The present invention relates to a modified T regulatory cell (Treg) in which the level of microRNA miR-142-5p (CAUAAAGUAGAAAGCACUACU) or a variant thereof is increased or decreased. Therapeutic uses of said modified Tregs are also provided, in particular in the treatment of autoimmune diseases and cancer. Populations of said Tregs and methods of preparing such Tregs are also provided.
-
公开(公告)号：US11253154B2
公开(公告)日：2022-02-22
申请号：US17003574
申请日：2020-08-26
IPC分类号： A61B5/00 , G01R33/34 , G01R33/56 , G01R33/565 , A61B5/055
摘要： A method and system for imaging a body using a magnetic resonance imaging (MRI) apparatus, including motion tracking of a target object of the body using MRI by generating an MRI image of a region of interest of the body by performing a weighted combination of a signal received by each coil of an MRI apparatus during an MRI scan.
-
公开(公告)号：US20220000372A1
公开(公告)日：2022-01-06
申请号：US17480313
申请日：2021-09-21
摘要： Embodiments and aspects described herein provide methods and systems for determining pressure difference across a tube arising from fluid flow within the tube, comprising: obtaining three-dimensional time dependent fluid velocity data at a plurality of points along the tube; processing the three-dimensional time dependent fluid velocity data to determine: i) a flow rate (Q) of the fluid through the tube; ii) the kinetic energy (K) of the fluid flow through the tube; iii) an advective energy rate (A) of the fluid flow through the tube; and iv) a viscous dissipation rate (V) pertaining to the fluid flow; and calculating the pressure difference in dependence on all of the flow rate (Q), kinetic energy (K), advective energy rate (A), and viscous dissipation rate (V). Further embodiments are also described.
-
公开(公告)号：US20210309984A1
公开(公告)日：2021-10-07
申请号：US17223743
申请日：2021-04-06
IPC分类号： C12N9/42 , G01N33/573
摘要： There is disclosed a peptide with mucolytic activity, The peptide comprising an amino acid sequence having at least 60% sequence identity to the amino add sequence defined in SEQ ID NO: 1, but does not consist of the amino sequence defined in SEQ ID NO: 2.
-
公开(公告)号：US20210261570A1
公开(公告)日：2021-08-26
申请号：US16616697
申请日：2018-05-30
发明人： Khondaker Mirazur RAHMAN , Shirin JAMSHIDI , Mark Benjamin LAWS , Kazi NAHAR , John Mark SUTTON , Charlotte HIND
IPC分类号： C07D498/06 , A61P31/04 , A61K45/06
摘要： The invention relates to antibiotic compounds of formula (A1) and pharmaceutically acceptable salts, solvates, tautomers and combinations thereof, wherein X and L are optional linkers and one of RA or R1 comprises Ar1, wherein Ar1 is an antibiotic resistance breaker moiety which comprises an optionally substituted C6-10 aryl, C7-13 aralkyl, C5-10 heteroaryl, C6-13 heteroaralkyl, C5-10 heterocyclyl, C6-13 heterocyclalkyl, C3-10 carbocyclyl, C4-13 carbocyclalkyl, —C(═NR′)—NR′R″ or —CH2—CH═CH2 group; wherein after administration of the compound to a bacterial infection this moiety reduces or prevents efflux. The invention also discloses pharmaceutical compositions comprising compounds of formula (A1) and the use of such compounds as medicaments, in particular, to treat bacterial infractions, such as drug-resistant bacterial infections.
-
公开(公告)号：US20210260369A1
公开(公告)日：2021-08-26
申请号：US17318550
申请日：2021-05-12
摘要： A portable, battery powered apparatus (10) generates an electrical signal between electrodes (15a, 15b) to be applied to the skin of a patient for reduction or prevention of snoring or obstructive sleep apnoea. The signal comprises electrical stimulation at a frequency of 1-100 Hz and the signal comprises a stimulation free period of at least 0.5 seconds every 20 seconds, avoiding muscle fatigue when used for long periods, e.g. overnight.
-
公开(公告)号：US20210177905A1
公开(公告)日：2021-06-17
申请号：US16761698
申请日：2018-11-06
发明人： Francesco DAZZI
摘要： A method is described for using live mesenchymal stromal cells (MSCs) in a way which allows for identification of patients likely to respond to immunosuppressive treatment using MSCs. The method involves contacting a sample from said patient with live MSCs in vitro, and determining whether the sample is able to induce at least some apoptosis to occur in live MSCs in vitro, or detection of elevated levels of prostaglandin E2 (PGE2). The ability of the sample to induce said apoptosis and/or elevated levels of PGE2 is indicative of responsiveness of said patient to said immunosuppressive treatment and/or indicative of fitness to recover. Also provided are apoptotic MSCs for use in the treatment of immune-mediated disease or conditions, such as allo-immune or autoimmune disease, or for the prevention or treatment of rejection of a transplanted organ; or in regenerative medicine to stimulate tissue repair. Methods for preparing pharmaceutical compositions comprising the apoptotic MSCs are also described and claimed.
-
公开(公告)号：US20210095252A1
公开(公告)日：2021-04-01
申请号：US16956500
申请日：2018-12-21
发明人： Fiona WATT , Christina PHILIPPEOS , Magnus LYNCH
摘要： Provided herein is a method of sorting human dermal fibroblasts, comprising (a) providing a cell population comprising human dermal fibroblasts; and (b) separating the human dermal fibroblasts into subpopulations based on expression of one or more cell-surface markers selected from CD39, CD36 and CD26. Also provided are isolated populations of human dermal papillary fibroblasts and cosmetic and therapeutic uses thereof.
-
-
-
-
-
-
-
-
-
搜索结果
269 条记录 (耗时 0.055 秒)